|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
GB8611832D0
(en)
|
1986-05-15 |
1986-06-25 |
Holland I B |
Polypeptide
|
|
US5037743A
(en)
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6011138A
(en)
|
1997-02-20 |
2000-01-04 |
Idec Pharmaceuticals Corporation |
Gamma-1 anti-human CD23 monoclonal antibodies
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
CN100574803C
(zh)
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
PT1731605E
(pt)
|
2004-03-31 |
2010-04-14 |
Int Inst Cancer Immunology Inc |
Péptidos antigénicos de cancro derivados de wt1
|
|
CA3255551A1
(en)
|
2010-03-26 |
2025-04-15 |
Memorial Sloan-Kettering Cancer Center |
MUC16 ANTIBODIES AND METHODS OF USE
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
CN105940102B
(zh)
|
2013-08-26 |
2020-02-18 |
海瑞克·亚柏坎 |
抗cd30嵌合抗原受体及其用途
|
|
US20160152725A1
(en)
|
2014-02-25 |
2016-06-02 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
GB201413335D0
(en)
|
2014-07-28 |
2014-09-10 |
Azotic Technologies Ltd |
Agricultural methods
|
|
WO2016016341A1
(en)
|
2014-07-29 |
2016-02-04 |
Cellectis |
EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
|
|
ES2818103T3
(es)
|
2015-01-16 |
2021-04-09 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
JP2018509148A
(ja)
|
2015-03-11 |
2018-04-05 |
セレクティスＣｅｌｌｅｃｔｉｓ |
患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
|
|
SG11201707538XA
(en)
|
2015-03-17 |
2017-10-30 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
TW201702272A
(zh)
|
2015-05-22 |
2017-01-16 |
美國紀念斯隆 凱特琳癌症中心 |
Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017025323A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
MX2018004503A
(es)
|
2015-10-15 |
2019-04-15 |
Us Health |
Receptores de antigeno quimerico anti-cd30.
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
TWI755547B
(zh)
|
2016-01-21 |
2022-02-21 |
美商輝瑞股份有限公司 |
靶向表皮生長因子受體變異體iii之嵌合型抗原受體
|
|
IL262061B2
(en)
|
2016-04-01 |
2023-03-01 |
Amgen Inc |
Chimeric flt-3 receptors and methods of using them
|
|
BR112018070948A2
(pt)
|
2016-04-13 |
2019-01-29 |
Orimabs Ltd. |
anticorpos anti-psma e utilização dos mesmos
|
|
ES2979068T3
(es)
|
2016-07-08 |
2024-09-24 |
Crage Medical Co Ltd |
Anticuerpos para anti-claudina 18A2 y utilización de los mismos
|
|
WO2018072025A1
(en)
|
2016-10-19 |
2018-04-26 |
The Governing Council Of The University Of Toronto |
Cd133-binding agents and uses thereof
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
TWI785009B
(zh)
|
2017-02-14 |
2022-12-01 |
美商凱特製藥公司 |
Ｃｄ７０結合分子及使用彼之方法
|
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
SG10202108528QA
(en)
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
|
KR20230008269A
(ko)
|
2017-08-07 |
2023-01-13 |
엔비이-테라퓨틱스 아게 |
생체 내 내성이 높은 항체 약물 결합체
|
|
JP2021505131A
(ja)
*
|
2017-12-08 |
2021-02-18 |
フェイト セラピューティクス，インコーポレイテッド |
増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
CN116836297A
(zh)
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
KR102351623B1
(ko)
|
2018-05-14 |
2022-01-14 |
주식회사 엘지에너지솔루션 |
분리막 기재가 없는 분리막
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
US20210269501A1
(en)
|
2018-06-25 |
2021-09-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
WO2020010284A1
(en)
|
2018-07-04 |
2020-01-09 |
Cytoimmune Therapeutics, LLC |
Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
|
|
US12036242B2
(en)
|
2018-07-05 |
2024-07-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
CAR T cells that target B-cell antigens
|
|
BR112021001338A2
(pt)
|
2018-07-26 |
2021-05-04 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
WO2020095249A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-liv1 immune cell cancer therapy
|
|
CN109468284A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
MX2021006194A
(es)
*
|
2018-12-02 |
2021-06-30 |
Fate Therapeutics Inc |
Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
|
|
AU2019397033B2
(en)
|
2018-12-12 |
2023-06-29 |
Kite Pharma, Inc. |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
CN109680002A
(zh)
|
2019-01-09 |
2019-04-26 |
上海怡豪生物科技有限公司 |
联合msln单链抗体和ccl19杀伤胃癌细胞的car载体及其构建方法和应用
|
|
CN109628492A
(zh)
|
2019-01-09 |
2019-04-16 |
上海怡豪生物科技有限公司 |
联合MSLN单链抗体和PD-1mAb杀伤胃癌细胞的CAR载体及其构建方法和应用
|
|
EP3911735A4
(en)
|
2019-01-16 |
2023-07-12 |
Beam Therapeutics, Inc. |
MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
|
|
SMT202400408T1
(it)
|
2019-01-16 |
2024-11-15 |
Caribou Biosciences Inc |
Anticorpo umanizzato bcma e cellule bcma-car-t
|
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
|
PH12021551720A1
(en)
|
2019-03-01 |
2022-03-28 |
Allogene Therapeutics Inc |
Dll3 targeting chimeric antigen receptors and binding agents
|
|
WO2020186204A1
(en)
|
2019-03-13 |
2020-09-17 |
Ulmert Hans David Staffan |
Prame binding molecules and uses thereof
|
|
KR20210139472A
(ko)
|
2019-04-11 |
2021-11-22 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
KR102773187B1
(ko)
|
2019-07-12 |
2025-02-27 |
퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. |
Cldn18.2 항체 및 이의 용도
|
|
CN114258429A
(zh)
*
|
2019-07-17 |
2022-03-29 |
菲特治疗公司 |
免疫效应细胞工程化和其用途
|
|
CN111363046A
(zh)
|
2020-03-11 |
2020-07-03 |
深圳宾德生物技术有限公司 |
靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|